FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
Syndicate content

Zyprexa news from FiercePharma

News

Under pharma earnings, basic problems

You've heard of see-through buildings. How about see-through pharma earnings? Though drug makers have been reporting increases to their bottom lines, investors are looking past the foreign-currency Read more...

Emerging markets drive global growth

Without emerging healthcare markets like China and India, global pharma would be in a world of hurt. The global market for meds reached $712 billion last year, according to a new report from IMS Read more...

Judge wary of certifying Zyprexa classes

Score one for Eli Lilly in federal court. A district judge says he probably won't give class-action status to patients and insurers who paid for Zyprexa for FDA-approved uses. And he doesn't expect Read more...
Tags: Zyprexa   lawsuits   Eli Lilly  

If J&J misled FDA, can patients sue?

Drug companies appear to be close to gaining a long-coveted prize: A shield against patient lawsuits. The Bush administration has been Read more...

Forbes to Big Pharma: Fess up

Big Pharma looks more and more like a big ostrich these days, Forbes suggests. The brouhaha over Vytorin and Zetia this week is a case in point. If the controversial Enhance study had proven Vytorin Read more...
Tags: Vytorin   Zocor   Zyprexa   Merck   Vioxx  

Lilly's Lechleiter: 'We're a biotech'

Tomorrow is the first day on the CEO job for Eli Lilly's John Lechleiter (Read more...
Tags: Eli Lilly   Zyprexa  

ALSO NOTED: Pre-emption fears helped spur Zyprexa deal; U.K. implant makers charge U.S. market;

> Scratching your head over the Zyprexa settlement in Alaska? Apparently, the prospect of a Supreme Court ruling that might sweep away state pharma suits helped spur the agreement. Read more...
Tags: Janet Woodcock   Zyprexa  

Judge: FDA can't police drugs alone

As Eli Lilly went up to bat in the big Zyprexa trial in Alaska, Read more...

Did Lilly chief support off-label promos?

You can bet incoming Eli Lilly CEO John Lechleiter (photo) spat out his Cheerios when he read the New York Times Read more...
Tags: Eli Lilly   Zyprexa  

Press Releases

PRESS RELEASE: Janssen's Risperdal and Astrazeneca's Seroquel Overtake Eli Lilly's Zyprexa

Janssen's Risperdal and Astrazeneca's Seroquel Overtake Eli Lilly's Zyprexa as the First-Line Antipsychotics of Choice in the Treatment for Schizophrenia Bristol Meyers Squibb/Otsuka Read more...

Get more Zyprexa coverage at: